In recent years, hospitals nationwide have been reporting an increase in life-threatening illnesses resulting from a deadly fungal infection caused by the yeast Candida auris that can enter the bloodstream. This yeast is difficult to identity and often does not respond to commonly used antifungal drugs, leading to high mortality.
According to the latest data from the Centers for Disease Control and Prevention (CDC), 166 confirmed and probable cases have been reported from 10 U.S. states; most have occurred in New York and New Jersey.as of Sep. 30. An additional 184 patients have been found to be colonized with C. auris by targeted screening in four states with clinical cases.
It is prevalent in patients who have been hospitalized a long time, have lines or tubes entering their body or have previously received antibiotics or antifungal medications.
Recognizing this emerging fungus as a global health threat, the Centers for Disease Control and Prevention has awarded Rutgers University a $300,000 contract over two years to address this deadly pathogen as part of its Antibiotic Resistance Solutions Initiative.
The Rutgers team – led by David Perlin, executive director and professor of the Public Health Research Institute at Rutgers New Jersey Medical School, and postdoctoral fellow Milena Kordalewska – will identify a new way to rapidly and accurately detect C. auris in swabs from patients and hospital environments. They also will analyze transmission patterns in New Jersey healthcare facilities using genetic fingerprint technology, in collaboration with Thomas Kirn, medical director of the Public Health Laboratory Service at the New Jersey Department of Health, associate professor of pathology and laboratory medicine at Rutgers Robert Wood Johnson Medical School and director of clinical microbiology and infectious disease diagnostics at Robert Wood Johnson University Hospital.
“What makes C. auris so alarming is that it is largely a drug-resistant, healthcare-associated infectious agent that can be easily transmitted between patients and the patients’ environment,” says Perlin. “This is extremely rare for a yeast.”
In 2009, C. auris was first described in a patient in Japan. There is documented transmission of C. auris to U.S. patients from healthcare facilities in India, Pakistan, South Africa and Venezuela.
“As reports of C. auris continue to mount within U.S. healthcare facilities, it is worrisome that the problem may grow much worse,” says Perlin. “The keys to containing the epidemic are infection control, the development of molecular tools to reliably and rapidly identify the pathogen and a better understanding of its genetic profile that facilitates transmission within hospital environments.”
Fungal infections often cause serious disease among patients with compromised immune systems or other debilitating conditions, resulting in high morbidity and mortality. Globally, nearly 1.4 million deaths a year are attributed to invasive fungal infections, which is on par with deadly diseases like tuberculosis.
- Candida auris in the US: 90 percent of isolates from NY, NJ
- Candida auris: Emerging fungal pathogen in England
- CDC issues alert to health practitioners: Be on the lookout for multidrug-resistant yeast Candida auris